The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index; 2 of the 18 sources its claims cite were checked for support.
Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations
Open accessPublished version of a preprint
Abstract
A key public health need is to identify individuals at high risk for a given disease to enable enhanced screening or preventive therapies. Because most common diseases have a genetic component, one important approach is to stratify individuals based on inherited DNA variation1. Proposed clinical applications have largely focused on finding carriers of rare monogenic mutations at several-fold increased risk. Although most disease risk is polygenic in nature2–5, it has not yet been possible to use polygenic predictors to identify individuals at risk comparable to monogenic mutations. Here, we develop and validate genome-wide polygenic scores for five common diseases. The approach identifies 8.0, 6.1, 3.5, 3.2, and 1.5% of the population at greater than threefold increased risk for coronary artery disease, atrial fibrillation, type 2 diabetes, inflammatory bowel disease, and breast cancer, respectively. For coronary artery disease, this prevalence is 20-fold higher than the carrier frequency of rare monogenic mutations conferring comparable risk6. We propose that it is time to contemplate the inclusion of polygenic risk prediction in clinical care, and discuss relevant issues. Genome-wide polygenic risk scores derived from GWAS data for five common diseases can identify subgroups of the population with risk approaching or exceeding that of a monogenic mutation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
25 Own result · 9 Not checked yet · 7 Own method · 3 Own interpretation · 2 No basis given · 1 Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“GPSCAD performed substantially better than two previously published polygenic scores for coronary artery disease that included 50 and 49,310 variants, respectively (Supplementary Table 7 and Supplementary Fig. 1).17,18”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Supportedcites [17] Tada, H. et al. Risk prediction by genetic risk scores for coronary heart disease is independent of self-reported family history. Eur. Heart J. 37, 561–567 (2016). source
The Methods (Modelling of genetic risk score) identify this paper’s GRS50 as a 50-SNP score for coronary heart disease, supporting its citation as the previously published 50-variant score. The comparison with GPSCAD is presented as the citing paper’s own analysis, not as a result attributed to this source. (LLM, conf=0.91)
- Supportedcites [18] Abraham, G. et al. Genomic prediction of coronary heart disease. Eur. Heart J. 37, 3267–3278 (2016). source
The citation identifies the previously published 49,310-variant score used as a comparator. Abraham et al. report generating that score in Abstract > Methods and results; the GPSCAD performance comparison is the citing authors’ own result, attributed to their supplementary table and figure. (LLM, conf=0.91)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, even for our middle-aged study population, practicing clinicians could not identify the 8% of individuals at ≥3-fold risk based on GPSCAD in the absence of genotype information (Supplementary Table 8).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The polygenic predictor identified 3.5% of the population at ≥3-fold risk and the top 1% had 3.30-fold risk. (Tables 2 & 3).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, 0.1% of women had ≥5-fold risk of breast cancer—corresponding to a breast cancer prevalence of 19.0% in this group versus 4.2% in the remaining 99.9% of the distribution.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The polygenic predictor identified 6.1% of the population at ≥3-fold risk and the top 1% had 4.63-fold risk (Tables 2 & 3).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, 0.1% of women had ≥5-fold risk of breast cancer—corresponding to a breast cancer prevalence of 19.0% in this group versus 4.2% in the remaining 99.9% of the distribution.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The polygenic predictor identified 3.2% of the population at ≥3-fold risk and the top 1% had 3.87-fold risk (Tables 2 & 3).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This predictor performed equivalently well in the testing dataset, with AUC of 0.81.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plainn = 288,978- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our results for CAD generalized to four other diseases: risk increased sharply in the right tail of the GPS distribution (Figure 3).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In our testing dataset, 19.8% of participants were at ≥3-fold increased risk for at least one of the five diseases studied (Table 2).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 8
- Probably not a substantial claim. 6
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The predictors had AUC ranging from 0.79 – 0.81 in the validation set, with the best predictor (GPSCAD) involving 6,630,150 variants (Supplementary Table 1).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelationaln = 120,280- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Across the population, GPSCAD is normally distributed with the empirical risk of CAD rising sharply in the right tail of the distribution, from 0.8% in the lowest percentile to 11.1% in the highest percentile (Figure 2).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“In order to analyze individuals with a relatively homogenous ancestry and owing to small percentages of non-British individuals, the present analysis was restricted to the white British ancestry individuals.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Testing cohort
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Whereas identifying carriers of rare monogenic mutations requires sequencing of specific genes and careful interpretation of the functional effects of mutations found, polygenic scores can be readily calculated for many diseases simultaneously, based on data from a single genotyping array.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The testing dataset was comprised of 288,978 UK Biobank Phase 2 participants distinct from those in the validation dataset described above.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Testing cohort
plainn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Our validation and testing was performed in the UK Biobank population.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“These initial efforts were hampered by three challenges: (i) the small size of initial genome-wide association studies (GWAS), which affected the precision of the estimated impact of individual variants on disease risk; (ii) limited computational methods for creating GPS; and (iii) lack of large datasets needed to validate and test GPS.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The results above show that, for a number of common diseases, polygenic risk scores can now identify a substantially larger fraction of the population than found by rare monogenic mutations, at comparable or greater disease risk.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The vast majority of common disease occurs in individuals without rare monogenic mutations.
In the paper
“Individuals who volunteered for the UK Biobank tended to be more healthy than the general population;27”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [27] Fry, A. et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am. J. Epidemiol. 186, 1026–1034 (2017). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“In both cases, it is important to recognize that the risk associated with a high polygenic score may not reflect a single underlying mechanism, but rather the combined influence of multiple pathways.28”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [28] Khera, A. V. & Kathiresan, S. Is coronary atherosclerosis one disease or many? Setting realistic expectations for precision medicine. Circulation 135, 1005–1007 (2017). source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“For example, we previously showed that a high polygenic risk for CAD may be offset by either of two interventions: adherence to a healthy lifestyle or cholesterol-lowering therapy with statin medications.19–21”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [19] Khera, A. V. et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N. Engl. J. Med. 375, 2349–2358 (2016). source
- Not checked yetcites [20] Mega, J. L. et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 385, 2264–2271 (2015). source
- Not checked yetcites [21] Natarajan, P. et al. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. Circulation 135, 2091–2101 (2017). source
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“UK Biobank samples were not included in any of the five discovery GWAS studies.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Polygenic score derivation
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“An important example is the presence of a familial hypercholesterolemia mutation in 0.4% of the population, which confers an up to 3-fold increased risk for coronary artery disease (CAD).6”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [6] Abul-Husn, N. S. et al. Genetic identification of familial hypercholesterolemia within a single U.S. health care system. Science 354, pii: aaf7000 (2016). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Another example is the p.E508K missense mutation in HNF1A, with carrier frequency of 0.1% of the general population and 0.7% of Latinos,8 which confers up to 5-fold increased risk for type 2 diabetes.9”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [8] Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016). source
- Not checked yetcites [9] Estrada, K. et al. Association of a low-frequency variant in HNF1A with type 2 diabetes in a Latino population. JAMA 311, 2305–2314 (2014). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
The vast majority of common disease occurs in individuals without rare monogenic mutations.
“Although ascertainment of monogenic mutations can be highly relevant for carriers and their families, the vast majority of disease occurs in those without such mutations.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, integrated models of PRS together with other lifestyle and clinical factors have enabled clinicians to more accurately quantify the risk of heart attack for patients;”
From Clinical use of current polygenic risk scores may exacerbate health disparities (2019) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This enthusiasm is driven by observations that a polygenic burden of LDL-increasing SNPs can confer monogenic-equivalent risk of cardiovascular disease, with polygenic scores improving clinical models for risk assessment and statin prescription that can reduce coronary heart disease and improve healthcare delivery efficiency5–7.”
From Clinical use of current polygenic risk scores may exacerbate health disparities (2019) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Using polygenic scores, it is now possible to combine information from millions of genomic variants to identify people whose overall polygenic risk of coronary artery disease is as high as that of patients with monogenic lipid disorders such as familial hypercholesterolemia [23].”
From Interpreting polygenic scores, polygenic adaptation, and human phenotypic differences (2019) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, they have contributed new approaches to risk prediction for adverse phenotypes related to heart disease [21–23].”
From Interpreting polygenic scores, polygenic adaptation, and human phenotypic differences (2019) · cites this paper as [23]
In the citing paper
“As described below, findings from GWAS have increasing translational impact through identification of novel therapeutic targets67, prioritization (and deprioritization) of existing ones68 and development of polygenic scores that quantify individual genetic risk69.”
From A brief history of human disease genetics (2020) · cites this paper as [69]
In the citing paper
“The development of robust polygenic scores for several common diseases has been catalysed by more precise per-variant effect estimates from larger GWAS datasets, improved algorithms for combining information across millions of single-nucleotide polymorphisms, and large-scale biobanks that support score validation69,146,147.”
From A brief history of human disease genetics (2020) · cites this paper as [69]
In the citing paper
“For example, a genome-wide polygenic score for heart attack, incorporating 6.6 million variants, indicates that 5% of European-descent individuals have a risk of future cardiac events equivalent to that seen in those with less frequent monogenic forms of hypercholesterolaemia69.”
From A brief history of human disease genetics (2020) · cites this paper as [69]
In the citing paper
“This paper used large-scale genetic data to demonstrate the clinical potential of the polygenic scores that can be constructed for many common diseases, emphasizing that, in some situations, the lifetime risk of disease for those with the highest scores approaches that of established monogenic disease.”
From A brief history of human disease genetics (2020) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Statistical analysis within the testing dataset
“For each disease, the GPS with the best discriminative capacity in the testing dataset was calculated in the testing dataset of 288,278 participants”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Testing cohort
“The testing dataset was comprised of 288,978 UK Biobank Phase 2 participants distinct from those in the validation dataset described above.”
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
A global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
Self-citationVos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728
Second-generation PLINK: rising to the challenge of larger and richer datasets
Chang, C. C., Chow, C. C., Tellier, L. C., Vattikuti, S., Purcell, S. M., & Lee, J. J. (2015) · Gigascience · doi:10.1186/s13742-015-0047-8 · Cited by 12,709
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
Self-citationVos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31678-6 · Cited by 7,253
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H. G., Cigarroa, J. E., Cleveland, J. C., CONTI, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,145
Self-citationCommon polygenic variation contributes to risk of schizophrenia and bipolar disorder
The International Schizophrenia Consortium (2009) · Nature · doi:10.1038/nature08185 · Cited by 4,821
Genetic studies of body mass index yield new insights for obesity biology
Study, T. L. C., Locke, A. E., The ADIPOGen Consortium, The AGEN-BMI Working Group, The CARDIOGRAMplusC4D Consortium, The CKDGen Consortium, The, G. L. G. C., The, I. C. B. P., The MAGIC Investigators, The MuTHER Consortium, et al. (2015) · Nature · doi:10.1038/nature14177 · Cited by 4,534
Self-citation
Cited by
Sorted by citations
Items 301–400 of 1,006
Microbiota in Gut‐Heart Axis: Metabolites and Mechanisms in Cardiovascular Disease
Kondapalli, N. B., Katari, V., Dalal, K. K., Paruchuri, S. M., & Thodeti, C. K. (2025) · Comprehensive physiology · doi:10.1002/cph4.70024 · Cited by 98
Challenges in IBD Research: Precision Medicine
Denson, L. A., Curran, M. E., McGovern, D. P. B., Koltun, W. A., Duerr, R. H., Kim, S. C., Sartor, R. B., Sylvester, F. A., Abraham, C., de Zoeten, E. F., et al. (2019) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izz078 · Cited by 94
Polygenic Hyperlipidemias and Coronary Artery Disease Risk
Ripatti, P., Rämö, J. T., Mars, N. J., Fu, Y., Lin, J., Söderlund, S., Benner, C., Surakka, I., Kiiskinen, T., Havulinna, A. S., et al. (2020) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.119.002725 · Cited by 93
Fritsche, L. G., Patil, S. B., Beesley, L. J., VandeHaar, P., Salvatore, M., Ma, Y., Peng, R. B., Taliun, D., Zhou, X., & Mukherjee, B. (2020) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2020.08.025 · Cited by 92
Genome-wide association studies of cardiovascular disease
Walsh, R., Jurgens, S. J., Erdmann, J., & Bezzina, C. R. (2023) · Physiological Reviews · doi:10.1152/physrev.00024.2022 · Cited by 95
The transferability of lipid loci across African, Asian and European cohorts
Kuchenbaecker, K. B., Telkar, N., Reiker, T., Walters, R. G., Lin, K., Eriksson, A., Gurdasani, D., Gilly, A., Southam, L., Tsafantakis, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12026-7 · Cited by 91
Biomarkers for Heart Failure Prognosis: Proteins, Genetic Scores and Non-coding RNAs
Shrivastava, A., Haase, T., Zeller, T., & Schulte, C. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.601364 · Cited by 92
Assessing Lung Cancer Absolute Risk Trajectory Based on a Polygenic Risk Model
Hung, R. J., Warkentin, M. T., Brhane, Y., Chatterjee, N., Christiani, D. C., Landi, M. T., Caporaso, N. E., Liu, G., Johansson, M., Albanes, D., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1237 · Cited by 91
Romeo, S., Vidal‐Puig, A., Husain, M., Ahima, R. S., Arca, M., Bhatt, D. L., Diehl, A. M., Fontana, L., Foo, R., Frühbeck, G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf314 · Cited by 93
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups, Bedognetti, D., Ceccarelli, M., Galluzzi, L., Lu, R. O., Palucka, K., Samayoa, J. A., Spranger, S., Warren, S. E., Wong, K., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0602-4 · Cited by 90
Emdin, C. A., Khera, A. V., Chaffin, M. D., Klarin, D. M., Natarajan, P., Aragam, K. G., Haas, M. E., Bick, A. G., Zekavat, S. M., Nomura, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03911-8 · Cited by 90
Self-citationGao, X., Huang, H., & Kim, H. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy422 · Cited by 94
Dickinson, D., Zaidman, S., Giangrande, E. J., Eisenberg, D. P., Gregory, M. D., & Berman, K. F. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19050527 · Cited by 90
Lewis, A. C. F., Perez, E. F., Prince, A. E. R., Flaxman, H. R., Gomez, L., Brockman, D., Chandler, P. D., Kerman, B. J., Lebo, M. S., Smoller, J. W., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01117-8 · Cited by 89
iPSC-derived organ-on-a-chip models for personalized human genetics and pharmacogenomics studies
Palasantzas, V. E. J. M., Tamargo-Rubio, I., Le, K. T. T., Slager, J., Wijmenga, C., Jonkers, I. H., Kumar, V., Fu, J., & Withoff, S. (2023) · Trends in Genetics · doi:10.1016/j.tig.2023.01.002 · Cited by 94
Defining and Achieving Health Equity in Genomic Medicine
Jooma, S., Hahn, M. J., Hindorff, L. A., & Bonham, V. L. (2019) · Ethnicity & Disease · doi:10.18865//ed.29.s1.173 · Cited by 91
Immunometabolic function of cholesterol in cardiovascular disease and beyond
Yvan‐Charvet, L., Bonacina, F., Guinamard, R., & Norata, G. D. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz127 · Cited by 89
Systematic Review of Polygenic Risk Scores for Type 1 and Type 2 Diabetes
Padilla-Martínez, F., Collin, F., Kwaśniewski, M., & Kretowski, A. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051703 · Cited by 93
A polygenic risk score predicts atrial fibrillation in cardiovascular disease
Marston, N., Garfinkel, A. C., Kamanu, F., Melloni, G. E. M., Roselli, C., Jarolím, P., Berg, D. D., Bhatt, D. L., Bonaca, M. P., Cannon, C. P., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac460 · Cited by 87
Self-citationEmerging role of genomic analysis in clinical evaluation of lean individuals with NAFLD
Vilarinho, S., Ajmera, V., Zheng, M., & Loomba, R. (2021) · Hepatology · doi:10.1002/hep.32047 · Cited by 85
Polygenic risk scores in psychiatry: Will they be useful for clinicians?
Fullerton, J. M., & Nürnberger, J. I. (2019) · F1000Research · doi:10.12688/f1000research.18491.1 · Cited by 87
Translating insights from neuropsychiatric genetics and genomics for precision psychiatry
Rees, E., & Owen, M. J. (2020) · Genome Medicine · doi:10.1186/s13073-020-00734-5 · Cited by 86
Polygenic architecture informs potential vulnerability to drug-induced liver injury
Koido, M., Kawakami, E., Fukumura, J., Noguchi, Y., Ohori, M., Nio, Y., Nicoletti, P., Aithal, G. P., Daly, A. K., Watkins, P. B., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1023-0 · Cited by 84
Gettler, K., Levantovsky, R. M., Moscati, A., Giri, M., Wu, Y., Hsu, N.-Y., Chuang, L.-S. F., Sazonovs, A., Venkateswaran, S., Korie, U. M., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.12.034 · Cited by 88
The Genetic Epidemiology of Type 2 Diabetes: Opportunities for Health Translation
Meigs, J. B. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1173-y · Cited by 82
ContIG: Self-supervised Multimodal Contrastive Learning for Medical Imaging with Genetics
Taleb, A., Kirchler, M., Monti, R., & Lippert, C. (2022) · 2022 IEEE/CVF Conference on Computer Vision and Pattern Recognition (CVPR) · doi:10.1109/cvpr52688.2022.02024 · Cited by 83
Human Genetics of Obesity and Type 2 Diabetes Mellitus
Ingelsson, E., & McCarthy, M. I. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.002090 · Cited by 86
Hahn, S.-J., Kim, S., Choi, Y. S., Lee, J., & Kang, J. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104383 · Cited by 89
Treff, N. R., Zimmerman, R., Bechor, E., Hsu, J., Rana, B., Jensen, J., Li, J., Samoilenko, A., Mowrey, W. R., Alstine, J. V., et al. (2019) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2019.04.004 · Cited by 82
Lu, T., Zhou, S., Wu, H., Forgetta, V., Greenwood, C. M. T., & Richards, J. B. (2020) · Genetics in Medicine · doi:10.1038/s41436-020-01007-7 · Cited by 82
Capalbo, A., Poli, M., Riera‐Escamilla, A., Shukla, V., Høffding, M. K., Krausz, C. G., Hoffmann, E. R., & Simón, C. (2020) · Human Reproduction Update · doi:10.1093/humupd/dmaa044 · Cited by 85
Biobanking with genetics shapes precision medicine and global health
Gallagher, C. S., Ginsburg, G. S., & Musick, A. (2024) · Nature Reviews Genetics · doi:10.1038/s41576-024-00794-y · Cited by 87
The distribution of common-variant effect sizes
O’Connor, L. J. (2021) · Nature Genetics · doi:10.1038/s41588-021-00901-3 · Cited by 81
He, Y., Lakhani, C. M., Rasooly, D., Manrai, A. K., Tzoulaki, I., & Patel, C. J. (2021) · Diabetes Care · doi:10.2337/dc20-2049 · Cited by 85
Polygenic risk scores: An overview from bench to bedside for personalised medicine
Cross, B., Turner, R., & Pirmohamed, M. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1000667 · Cited by 86
Epigenetics of Early Cardiometabolic Disease: Mechanisms and Precision Medicine
Baccarelli, A., & Ordovás, J. M. (2023) · Circulation Research · doi:10.1161/circresaha.123.322135 · Cited by 83
Mapping genetic effects on cellular phenotypes with “cell villages”
Mitchell, J. M., Nemesh, J., Ghosh, S., Handsaker, R. E., Mello, C. J., Meyer, D., Raghunathan, K., de Rivera, H., Tegtmeyer, M., Hawes, D., et al. (2020) · doi:10.1101/2020.06.29.174383 · Cited by 63
Lello, L., Raben, T. G., Yong, S. Y., Tellier, L. C. A. M., & Hsu, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-51258-x · Cited by 82
Differential epigenetic factors in the prediction of cardiovascular risk in diabetic patients
Claudio Napoli, A., Benincasa, G., Schiano, C., & Salvatore, M. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz062 · Cited by 80
Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J. M., Capodanno, D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.10.016 · Cited by 89
The clinical utility of polygenic risk scores in genomic medicine practices: a systematic review
Kumuthini, J., Zick, B., Balasopoulou, A., Chalikiopoulou, C., Dandara, C., El‐Kamah, G. Y., Findley, L., Κάτσιλα, Θ., Li, R., Maceda, E. B. G., et al. (2022) · Human Genetics · doi:10.1007/s00439-022-02452-x · Cited by 83
Metabolic and proteomic signatures of type 2 diabetes subtypes in an Arab population
Zaghlool, S. B., Halama, A., Stephan, N., Guðmundsdóttir, V., Gudnason, V. G., Jennings, L. L., Thangam, M., Ahlqvist, E., Malik, R. A., Albagha, O., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34754-z · Cited by 81
Innes, H. A., Buch, S., Hutchinson, S. J., Guha, I. N., Morling, J. R., Barnes, E. J., Irving, W. L., Forrest, E. H., Pedergnana, V., Goldberg, D. J., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.06.014 · Cited by 79
Towards equitable and trustworthy genomics research
Atutornu, J., Milne, R., Costa, A., Patch, C., & Middleton, A. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103879 · Cited by 82
Ju, D., Hui, D., Hammond, D. A., Wonkam, A., & Tishkoff, S. A. (2022) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-122220-112550 · Cited by 85
Multi-PGS enhances polygenic prediction by combining 937 polygenic scores
Albiñana, C., Zhu, Z., Schork, A. J., Ingason, A., Aschard, H., Brikell, I., Bulik, C. M., Petersen, L. V., Agerbo, E., Grove, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40330-w · Cited by 84
Sex differences in the genetic and molecular mechanisms of coronary artery disease
Sakkers, T. R., Mokrý, M., Civelek, M., Erdmann, J., Pasterkamp, G., Benavente, E. D., & den Ruijter, H. M. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117279 · Cited by 81
Ντάλλα, Ι., Kanoni, S., Zeng, L., Giannakopoulou, O., Danesh, J., Watkins, H. C., Samani, N. J., Deloukas, P., & Schunkert, H. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.512 · Cited by 79
Utility and First Clinical Application of Screening Embryos for Polygenic Disease Risk Reduction
Treff, N. R., Eccles, J., Lello, L., Bechor, E., Hsu, J., Plunkett, K., Zimmerman, R., Rana, B., Samoilenko, A., Hsu, S., et al. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00845 · Cited by 78
Epigenetic and Transcriptional Networks Underlying Atrial Fibrillation
van Ouwerkerk, A. F., Hall, A. W., Kadow, Z. A., Lazarevic, S., Reyat, J. S., Tucker, N. R., Nadadur, R. D., Bosada, F. M., Bianchi, V., Ellinor, P. T., et al. (2020) · Circulation Research · doi:10.1161/circresaha.120.316574 · Cited by 79
Self-citationLee, S.-H., Turpin, W., Espin‐Garcia, O., Garay, J. A. R., Smith, M. I., Leibovitzh, H., Goethel, A., Turner, D., Mack, D. R., Deslandres, C., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.009 · Cited by 80
Liang, Y., Pividori, M., Manichaikul, A. W., Palmer, A. A., Cox, N. J., Wheeler, H. E., & Im, H. K. (2022) · Genome biology · doi:10.1186/s13059-021-02591-w · Cited by 79
Genetics of Intracranial Aneurysms
Bakker, M. K., & Ruigrok, Y. M. (2021) · Stroke · doi:10.1161/strokeaha.120.032621 · Cited by 83
Genome-wide risk prediction of common diseases across ancestries in one million people
Mars, N., Kerminen, S., Feng, Y. A., Kanai, M., Läll, K., Thomas, L. F., Skogholt, A. H., Parolo, P. D. B., Neale, B. M., Smoller, J. W., et al. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100118 · Cited by 83
Klarin, D. M., Devineni, P., Sendamarai, A. K., Angueira, A. R., Graham, S. E., Shen, Y. H., Levin, M. G., Pirruccello, J. P., Surakka, I. L., Karnam, P., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01420-z · Cited by 80
Self-citationCho, S. M. J., Koyama, S., Honigberg, M. C., Surakka, I. L., Haidermota, S., Ganesh, S., Patel, A. P., Bhattacharya, R., Lee, H., Kim, H. C., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad380 · Cited by 80
Self-citationJabbour, G., Nolin-Lapalme, A., Tastet, O., Corbin, D., Jordà, P., Sowa, A., Delfrate, J., Busseuil, D., Hussin, J., Dubé, M., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae595 · Cited by 85
Forgetta, V., Keller‐Baruch, J., Forest, M., Durand, A., Bhatnagar, S., Kemp, J. P., Nethander, M., Evans, D. S., Morris, J. A., Kiel, D. P., et al. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003152 · Cited by 78
Defining Heterogeneity Among Women With Gestational Diabetes Mellitus
Powe, C. E., Hivert, M., & Udler, M. S. (2020) · Diabetes · doi:10.2337/dbi20-0004 · Cited by 79
Whole-genome sequencing analysis of semi-supercentenarians
Garagnani, P., Marquis, J., Delledonne, M., Pirazzini, C., Marasco, E., Kwiatkowska, K. M., Iannuzzi, V., Bacalini, M. G., Valsesia, A., Carayol, J., et al. (2021) · eLife · doi:10.7554/elife.57849 · Cited by 78
Abraham, G., Rutten‐Jacobs, L. C. A., & Inouye, M. (2021) · Stroke · doi:10.1161/strokeaha.120.032619 · Cited by 78
Khunsriraksakul, C., Li, Q., Markus, H., Patrick, M. T., Sauteraud, R., McGuire, D., Wang, X., Wang, C., Wang, L., Chen, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36306-5 · Cited by 79
Polygenic risk alters the penetrance of monogenic kidney disease
Khan, A., Shang, N., Nestor, J. G., Weng, C., Hripcsak, G. M., Harris, P. C., Gharavi, A. G., & Kiryluk, K. (2023) · Nature Communications · doi:10.1038/s41467-023-43878-9 · Cited by 79
Next-generation drug repurposing using human genetics and network biology
Nabirotchkin, S., Peluffo, A. E., Rinaudo, P., Yu, J., Hajj, R., & Cohen, D. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.12.004 · Cited by 77
Genetic basis of mitochondrial diseases
Gušić, M., & Prokisch, H. (2021) · FEBS Letters · doi:10.1002/1873-3468.14068 · Cited by 79
Schultebraucks, K., Choi, K. W., Galatzer‐Levy, I. R., & Bonanno, G. A. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.0228 · Cited by 78
Deep learning-based polygenic risk analysis for Alzheimer’s disease prediction
Zhou, X., Chen, Y., Ip, F. C. F., Jiang, Y., Cao, H., Lv, G., Zhong, H., Chen, J., Tao, Y., Chen, Y., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00269-x · Cited by 79
The genetic architecture of vitiligo
Roberts, G. H. L., Santorico, S. A., & Spritz, R. A. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12848 · Cited by 76
The emerging field of polygenic risk scores and perspective for use in clinical care
Yanes, T., McInerney-Leo, A. M., Law, M. H., & Cummings, S. A. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa136 · Cited by 75
Choi, J., Jia, G., Wen, W., Shu, X., & Zheng, W. (2020) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqaa404 · Cited by 78
Adegunsoye, A., Kropski, J. A., Behr, J., Blackwell, T. S., Corte, T. J., Cottin, V., Glanville, A. R., Glassberg, M. K., Griese, M., Hunninghake, G. M., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202401-0238so · Cited by 82
A scalable variational inference approach for increased mixed-model association power
Loya, H., Kalantzis, G., Cooper, F., & Palamara, P. F. (2025) · Nature Genetics · doi:10.1038/s41588-024-02044-7 · Cited by 92
DOMINO: a network‐based active module identification algorithm with reduced rate of false calls
Levi, H., Elkon, R., & Ron Shamir, A. (2021) · Molecular Systems Biology · doi:10.15252/msb.20209593 · Cited by 76
Liu, C., Zeinomar, N., Chung, W. K., Kiryluk, K., Gharavi, A. G., Hripcsak, G. M., Crew, K. D., Shang, N., Khan, A., Fasel, D. A., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.19084 · Cited by 75
eXclusionarY: 10 years later, where are the sex chromosomes in GWASs?
Sun, L., Wang, Z., Lu, T., Manolio, T. A., & Paterson, A. D. (2023) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2023.04.009 · Cited by 76
Parkinson’s Disease is Predominantly a Genetic Disease
Lim, S., & Klein, C. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-230376 · Cited by 75
Juul Rasmussen, I., Rasmussen, K. L., Nordestgaard, B. G., Tybjærg-Hansen, A., & Frikke-Schmidt, R. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa695 · Cited by 73
Utility of polygenic embryo screening for disease depends on the selection strategy
Lencz, T., Backenroth, D., Granot‐Hershkovitz, E., Green, A., Gettler, K., Cho, J. H., Weissbrod, O., Zuk, O., & Carmi, S. (2021) · eLife · doi:10.7554/elife.64716 · Cited by 74
Polygenic risk scores for the prediction of cardiometabolic disease
O’Sullivan, J. W., Ashley, E. A., & Elliot, P. M. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac648 · Cited by 74
Clinical utility of polygenic risk scores: a critical 2023 appraisal
Koch, S., Schmidtke, J., Krawczak, M., & Caliebe, A. (2023) · Journal of Community Genetics · doi:10.1007/s12687-023-00645-z · Cited by 80
Rare penetrant mutations confer severe risk of common diseases
Fiziev, P. P., McRae, J. F., Ulirsch, J. C., Dron, J. S., Hamp, T., Yang, Y., Wainschtein, P., Ni, Z., Schraiber, J. G., Gao, H., et al. (2023) · Science · doi:10.1126/science.abo1131 · Cited by 79
Self-citationPuri, R., Bansal, M., Mehta, V., Duell, P. B., Wong, N. D., Iyengar, S., Kalra, D. K., Nair, D. R., Nanda, N. C., Narula, J., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.01.006 · Cited by 75
Association Between Polygenic Risk Score and Risk of Myopia
Mojarrad, N. G., Plotnikov, D., Williams, C., & Guggenheim, J. A. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2019.4421 · Cited by 75
Omics phenotyping in heart failure: the next frontier
Bayés‐Genís, A., Liu, P. P., Lanfear, D. E., de Boer, R. A., González, A., Thum, T., Emdin, M., & Januzzi, J. L. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa270 · Cited by 72
Zhou, G., & Zhao, H. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009697 · Cited by 73
Zhuang, P., Liu, X., Li, Y., Wan, X., Wu, Y., Wu, F., Zhang, Y., & Jiao, J. (2021) · Diabetes Care · doi:10.2337/dc21-1051 · Cited by 75
The potential of polygenic scores to improve cost and efficiency of clinical trials
Fahed, A. C., Philippakis, A., & Khera, A. V. (2022) · Nature Communications · doi:10.1038/s41467-022-30675-z · Cited by 72
Self-citationMolecular Biomarkers for Cardiometabolic Disease: Risk Assessment in Young Individuals
Tahir, U. A., & Gerszten, R. E. (2023) · Circulation Research · doi:10.1161/circresaha.123.322000 · Cited by 78
Nightingale Health Biobank Collaborative Group, Barrett, J. C., Esko, T., Fischer, K., Jostins-Dean, L., Jousilahti, P., Julkunen, H., Jääskeläinen, T., Kangas, A. J., Kerimov, N., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54357-0 · Cited by 74
Lázaro‐Muñoz, G., Pereira, S., Carmi, S., & Lencz, T. (2020) · Genetics in Medicine · doi:10.1038/s41436-020-01019-3 · Cited by 71
Fanelli, G., Benedetti, F., Kasper, S., Zohar, J., Souery, D., Montgomery, S., Albani, D., Forloni, G., Ferentinos, P. P., Rujescu, D., et al. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110170 · Cited by 72
Torres, J., Halfvarson, J., Rodríguez–Lago, I., Hedin, C. R. H., Jess, T., Dubinsky, M. C., Croitoru, K., & Colombel, J. (2021) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjab048 · Cited by 72
Pathogenic variants in actionable MODY genes are associated with type 2 diabetes
Bonnefond, A., Boissel, M., Bolze, A., Durand, E., Toussaint, B., Vaillant, E., Gaget, S., Graeve, F. D., Dechaume, A., Allegaert, F., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00294-3 · Cited by 75
Polygenic risk score association with multiple sclerosis susceptibility and phenotype in Europeans
Shams, H., Shao, X., Santaniello, A., Kirkish, G., Harroud, A., Ma, Q., Isobe, N., Alexander, J., Bove, R. M., Baranzini, S. E., et al. (2022) · Brain · doi:10.1093/brain/awac092 · Cited by 75
Wang, Y., Kanai, M., Tan, T., Kamariza, M., Tsuo, K., Yuan, K., Zhou, W., Okada, Y., The Biobank Japan Project, Huang, H., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100408 · Cited by 73
Haas, O. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03136 · Cited by 70
Sex-dependent autosomal effects on clinical progression of Alzheimer’s disease
Fan, C. C., Banks, S. J., Thompson, W. K., Chen, C., McEvoy, L. K., Tan, C. H., Kukull, W. A., Bennett, D. A. A., Farrer, L. A., Mayeux, R. P., et al. (2020) · Brain · doi:10.1093/brain/awaa164 · Cited by 70
Nakamura, T., & Takata, A. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02005-2 · Cited by 72
Masana, L., Zamora, A., Plana, N., Comas‐Cufí, M., García-Gil, M., Martí‐Lluch, R., Ponjoan, A., Alves‐Cabratosa, L., Elosúa, R., Marrugat, J., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071080 · Cited by 68
Mouse Systems Genetics as a Prelude to Precision Medicine
Li, H., & Auwerx, J. H. (2020) · Trends in Genetics · doi:10.1016/j.tig.2020.01.004 · Cited by 72
Metadata
- Authors
- Khera, A. V., Chaffin, M., Aragam, K. G., Haas, M. E., Roselli, C., Choi, S. H., Natarajan, P., Lander, E. S., Lubitz, S. A., Ellinor, P. T., & Kathiresan, S.
- Affiliations
- Broad Institute (US)
- Corresponding author
- Kathiresan, Sekar
- ORCID
- Venue
- Nature Genetics
- Published
- 2018-08-13
- Volume
- 50
- Issue
- 9
- Pages
- 1219-1224
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- PMC
- PMC6128408
- OpenAlex
- W2886752110
- Semantic Scholar
- d5eb49c11d070114e2ff46224099895c6b4b1558
- Cited by
- 2,953
- References
- 46
- Citations by year
- 2026: 276 · 2025: 290 · 2024: 363 · 2023: 362 · 2022: 433 · 2021: 411 · 2020: 451 · 2019: 307 · 2018: 57
- FWCI
- 189.86
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, other-oa)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- PMC
- Funders
- Doris Duke Charitable Foundation (2014105)
- Massachusetts General Hospital (HL007208)
- Harvard Catalyst (TR001100)
- Vertex Pharmaceuticals
- KR Foundation
- National Institutes of Health (KL2TR001100, HL0-07734, HL007208, T32-HL007734)
- National Heart, Lung, and Blood Institute (R01HL127564, HL007208, HL127564, R01HL128914, T-32HL007734, K08HL140203, HL007734, K23HL114724, K24HL105780, R01HL142711, R01HL092577, T32HL007208, R01HL139731)
- National Human Genome Research Institute (UM1HG008895)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and phenotypic traits in livestock
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- polygenic risk score, monogenic mutations, common diseases, coronary artery disease, atrial fibrillation, type 2 diabetes, inflammatory bowel disease, breast cancer, high-risk individuals, clinical risk stratification
- MeSH terms
- Adult, Aged, Disease, Female, Humans, Male, Middle Aged, Mutation, Risk Factors, Genetic Predisposition to Disease, Multifactorial Inheritance, Polymorphism, Single Nucleotide, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
